TYME - タイム・テクノロジ―ズ （Tyme Technologies Inc.） タイム・テクノロジ―ズTYMEのチャート
TYMEの企業情報
| symbol | TYME |
|---|---|
| 会社名 | Tyme Technologies Inc （タイム・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Tyme Technologies Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program SM-88 is a first-in-class combination therapy in Phase II development for prostate cancer and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast lung prostate gastric esophageal and pancreatic cancers. タイム・テクノロジ―ズは米国のバイオ医薬品企業。臨床段階で、がん治療の開発・商業化に従事する。同社開発の「SM-88」はがん治療以外の分野で認可済の3種類の市販薬と独自の分子の組み合わせ。がん細胞にのみ浸透するように設計されている「SM-88」は、健康な体組織に毒性の影響を与えず、がん細胞を攻撃するメカニズムを導入している。本社所在地はニューヨーク。 Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system. With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19. |
| 本社所在地 | 17 State Street 7th Floor New York NY 10004 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 646-205-1603 |
| 設立年月日 | 40848 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 11人 |
| url | www.tymetechnologiesinc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tyme |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -22.88491 |
| 終値（lastsale） | 2.34 |
| 時価総額（marketcap） | 236869960.86 |
| 時価総額 | 時価総額（百万ドル） 266.22560 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 244.05633 |
| 当期純利益 | 当期純利益（百万ドル） -22.81936 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 30 June 2018 Tyme Technologies Inc revenues was not reported. Net loss increased from $2.9M to $6.7M. Higher net loss reflects Research and development - Balancing val increase from $775K to $2.3M (expense) General and administrative - Balancing v increase of 83% to $2M (expense) Stock-based Compensation in SGA increase from $807K to $1.7M (expense). |
TYMEのテクニカル分析
TYMEのニュース
Syros Pharmaceuticals - A Major Vote Of Confidence From Insiders (NASDAQ:SYRS) 2022/09/20 10:45:48 Seeking Alpha
Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. Read why SYRS presents an interesting investment opportunity.
These strategies will help Tyme Technologies Inc. (TYME) succeed 2022/09/19 13:48:00 US Post News
As of Friday, Tyme Technologies Inc.’s (NASDAQ:TYME) stock closed at $0.31, up from $0.29 the previous day. While Tyme Technologies Inc. has overperformed by 8.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TYME fell by -70.12%, with highs and lows ranging from $1.14 to $0.22, […]
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger 2022/09/15 20:17:59 Seeking Alpha
Shareholders of Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) on Thursday voted in favor of the merger between the two biotech companies.SYRS and TYME stock gained more…
Syros and Tyme Technologies Announce Stockholder Approval of Merger 2022/09/15 20:01:00 Business Wire
CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merge
Tyme Technologies Inc.’s Stock Gains 12.05%, But It May Still Be Worth Investing In. 2022/09/13 18:00:00 Stocks Register
The trading price of Tyme Technologies Inc. (NASDAQ:TYME) floating higher at last check on Tuesday, September 13, closing at $0.29, 12.05% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $0.2441 and $0.2597. In examining the 52-week price action we see that … Tyme Technologies Inc.’s Stock Gains 12.05%, But It May Still Be Worth Investing In. Read More »
Syros Pharmaceuticals - A Major Vote Of Confidence From Insiders (NASDAQ:SYRS) 2022/09/20 10:45:48 Seeking Alpha
Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. Read why SYRS presents an interesting investment opportunity.
These strategies will help Tyme Technologies Inc. (TYME) succeed 2022/09/19 13:48:00 US Post News
As of Friday, Tyme Technologies Inc.’s (NASDAQ:TYME) stock closed at $0.31, up from $0.29 the previous day. While Tyme Technologies Inc. has overperformed by 8.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TYME fell by -70.12%, with highs and lows ranging from $1.14 to $0.22, […]
Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger 2022/09/15 20:17:59 Seeking Alpha
Shareholders of Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) on Thursday voted in favor of the merger between the two biotech companies.SYRS and TYME stock gained more…
Syros and Tyme Technologies Announce Stockholder Approval of Merger 2022/09/15 20:01:00 Business Wire
CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merge
Tyme Technologies Inc.’s Stock Gains 12.05%, But It May Still Be Worth Investing In. 2022/09/13 18:00:00 Stocks Register
The trading price of Tyme Technologies Inc. (NASDAQ:TYME) floating higher at last check on Tuesday, September 13, closing at $0.29, 12.05% higher than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $0.2441 and $0.2597. In examining the 52-week price action we see that … Tyme Technologies Inc.’s Stock Gains 12.05%, But It May Still Be Worth Investing In. Read More »
Why Are Tyme Technologies Shares Staring At 52-Week Low 2022/01/26 12:25:39 Benzinga
TYME Technologies Inc (NASDAQ: TYME ) will discontinue SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC). The trial''s sponsor, Pancreatic Cancer Action Network (PanCAN), terminated the arm due to futility compared to the control of the standard of Full story available on Benzinga.com
Volume Movers: Tyme Technologies, Inc. (NASDAQ:TYME), Altice USA, Inc. (NYSE:ATUS) 2021/12/24 04:31:37 Stock Equity
Tyme Technologies, Inc. (NASDAQ:TYME) with the stream of -3.63% also noticed, India Altice USA, Inc. (NYSE:ATUS) encountered a rapid change of 2.22% in the last hour of Thursdays trading session. The post Volume Movers: Tyme Technologies, Inc. (NASDAQ:TYME), Altice USA, Inc. (NYSE:ATUS) appeared first on Stocks Equity .
Tyme Technologies Inc. (NASDAQ: TYME)s Stock Is Down -38.25% Since The Beginning Of The Year, Likely To Sustain The Trend In 2021 2021/12/18 13:00:00 Marketing Sentinel
During the last session, Tyme Technologies Inc. (NASDAQ:TYME)s traded shares were 0.79 million, with the beta value of the company hitting 0.92. At the end of the trading day, the stocks price was $0.70, reflecting an intraday loss of -0.85% or -$0.01. The 52-week high for the TYME share is $4.99, that puts it down Tyme Technologies Inc. (NASDAQ: TYME)s Stock Is Down -38.25% Since The Beginning Of The Year, Likely To Sustain The Trend In 2021 Read More »
Volume Sizzler: Tyme Technologies, Inc. (NASDAQ:TYME), Chewy, Inc. (NYSE:CHWY) 2021/12/15 00:01:07 Stock Equity
Tyme Technologies, Inc. (NASDAQ:TYME) with the stream of -1.30% also noticed, India Chewy, Inc. (NYSE:CHWY) encountered a rapid change of -0.71% in the last hour of Tuesdays trading session. Tyme The post Volume Sizzler: Tyme Technologies, Inc. (NASDAQ:TYME), Chewy, Inc. (NYSE:CHWY) appeared first on Stocks Equity .
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections 2021/12/14 11:50:00 Business Wire
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections. The Company believes that TYME-19, a synthetic bile acid, may have differentiated mechanisms that could offer alternatives for COVID-19 infected patients who may not be served by current and emerging oral agents. Bile